Cargando…

Digital tools, multidisciplinarity and innovation for communicating vaccine safety in the COVID-19 era

The research on the anti-SARS-CoV-2 vaccines and their commercialization is an opportunity to test and consolidate the current knowledge along with the diverse available tools related to vaccine communication. In this paper we explore the value of a multidisciplinary approach in this field: vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gesualdo, Francesco, Bucci, Lucie M., Rizzo, Caterina, Tozzi, Alberto E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Coronavirus – Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920147/ https://www.ncbi.nlm.nih.gov/pubmed/33764272 http://dx.doi.org/10.1080/21645515.2020.1865048

Ejemplares similares

COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety
por: Kricorian, Katherine, et al.
Publicado: (2021)

Online mis/disinformation and vaccine hesitancy in the era of COVID-19: Why we need an eHealth literacy revolution
por: Dib, Fadia, et al.
Publicado: (2021)

Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination
por: Ralise, Ana Eliza Garcia, et al.
Publicado: (2023)

Multidisciplinarity
por: Santos, Luisa
Publicado: (2018)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Chatting with ChatGPT to learn about safety of COVID-19 vaccines – A perspective
por: Salas, Antonio, et al.
Publicado: (2023)

Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
por: Gilbert, Danielle, et al.
Publicado: (2023)

Confidence in COVID-19 vaccine effectiveness and safety and its effect on vaccine uptake in Tanzania: A community-based cross-sectional study
por: Mtei, Monica, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023)

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
por: Xu, Fang, et al.
Publicado: (2022)

Factors influencing attitudes toward vaccine safety and vaccine effectiveness amongst UK healthcare professionals prior to and at the time of COVID-19 vaccine rollout: Insights from the CoPE-HCP cohort study
por: Collett, George, et al.
Publicado: (2023)

Digital Surveillance Through an Online Decision Support Tool for COVID-19 Over One Year of the Pandemic in Italy: Observational Study
por: Tozzi, Alberto Eugenio, et al.
Publicado: (2021)

Digital tools in the informed consent process: a systematic review
por: Gesualdo, Francesco, et al.
Publicado: (2021)

COVID-19 vaccine demand protest might have increased vaccine acceptance and uptake in South Africa
por: Mavundza, Edison Johannes, et al.
Publicado: (2022)

Safety evaluation of COVID-19 vaccination during early pregnancy: A single-center prospective cohort study of Chinese pregnant women
por: Lu, Ling, et al.
Publicado: (2023)

Status of COVID-19 vaccination around South Asia
por: Hayat, Mahnoor, et al.
Publicado: (2022)

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults
por: Yassini, Patrick, et al.
Publicado: (2023)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

SARS-CoV-2 vaccination in the context of original antigenic sin
por: Petráš, Marek, et al.
Publicado: (2021)

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
por: Thuluva, Subhash, et al.
Publicado: (2023)

Resolving sex and gender bias in COVID-19 vaccines R&D and beyond
por: Vijayasingham, Lavanya, et al.
Publicado: (2022)

Low coverage of COVID-19 vaccines in Africa: current evidence and the way forward
por: Lawal, Lukman, et al.
Publicado: (2022)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
por: Ripabelli, Giancarlo, et al.
Publicado: (2023)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Potential changes in vaccine access and policy landscape in Thailand post COVID-19 pandemic
por: Kategeaw, Warittakorn, et al.
Publicado: (2022)

Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
por: Maguire, Greg
Publicado: (2022)

Victorian Specialist Immunisation Services (VicSIS) – bolstering adult clinics for COVID-19 vaccines
por: Gordon, Sally F., et al.
Publicado: (2022)

Impact of a focus education in Zoom on COVID-19 vaccine hesitancy in Hong Kong parents of the preschoolers
por: Wong, Wilfred Hing-sang, et al.
Publicado: (2022)

Addressing an urgent global public health need: Strategies to recover routine vaccination during the COVID-19 pandemic
por: Larson, Anna, et al.
Publicado: (2021)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines
por: Hossain, Md. Jamal, et al.
Publicado: (2022)

Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update
por: Mohapatra, Ranjan K., et al.
Publicado: (2022)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

COVID-19 vaccination hesitancy among Italian parents: A systematic review and meta-analysis
por: Bianchi, Francesco Paolo, et al.
Publicado: (2023)

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
por: Yu, Su-Yeon, et al.
Publicado: (2022)

Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infection
por: Mancon, A., et al.
Publicado: (2022)

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public’s intention to take booster vaccines: A cross-sectional analysis
por: Salman, Muhammad, et al.
Publicado: (2023)

Can Digital Tools Be Used for Improving Immunization Programs?
por: Tozzi, Alberto E., et al.
Publicado: (2016)

Correlates of uptake of COVID-19 vaccines and motivation to vaccinate among Malawian adults
por: Whitehead, Hannah S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qtj0qffmlfq24250ephnbjp7gk